Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Lymphocyte function-associated antigen 1/Intercellular adhesion molecule 1 (LFA-1/ICAM-1) adhesion system is a critical receptor-ligand complex that mediates leukocyte trafficking, extravasation, and immunological synapse formation. LFA-1 (also known as integrin alpha-L/beta-2 or CD11a/CD18) is expressed on the surface of leukocytes, while its primary ligand, ICAM-1 (CD54), is expressed on endothelial cells, epithelial cells, and antigen-presenting cells. Under inflammatory conditions, the interaction between LFA-1 and ICAM-1 is upregulated, facilitating the recruitment and activation of T-cells at sites of inflammation. Consequently, this adhesion system plays a pivotal role in the pathogenesis of various inflammatory and autoimmune disorders, such as dry eye disease, psoriasis, and rheumatoid arthritis. Therapeutic targeting of this system has led to the development of drugs like lifitegrast, a topically administered small molecule antagonist approved for dry eye disease, and efalizumab, a monoclonal antibody previously approved for psoriasis but later withdrawn due to safety concerns. Systemic inhibition of this pathway carries risks of severe immunosuppression and progressive multifocal leukoencephalopathy (PML), whereas localized topical administration minimizes systemic exposure and associated toxicities.
Competitive or allosteric inhibition of the interaction between the leukocyte integrin LFA-1 (CD11a/CD18) and its endothelial/epithelial ligand ICAM-1 (CD54). This blockade prevents T-cell adhesion, migration, and activation, thereby reducing downstream inflammatory cytokine release.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Lymphocyte function-associated antigen 1/Intercellular adhesion molecule 1 adhesion system (LFA-1/ICAM-1).